Laborie Announces First Procedures in ENDURE 1 Study with the Optilume® Ureteric Drug-Coated Balloon
PORTSMOUTH, N.H., Oct. 28, 2025 /PRNewswire/ -- Laborie Medical Technologies, a global leader in diagnostic and therapeutic devices, today announced the successful completion of the first procedures ...
Findings Published in Journal of Endourology Support Minimally Invasive Alternative to Repeat Endoscopic Procedures PORTSMOUTH, N.H., May 8, 2025 /PRNewswire/ -- Laborie Medical Technologies Corp.
Newswise — MINNEAPOLIS, July 18, 2023 /PRNewswire/ -- Urotronic, Inc., a Minnesota-based medical device company pioneering the application of its drug-coated balloon technologies for use in ...
Newswise — August 10, 2023 – Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic ...
Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a ...
Laborie Announces First Procedures in ENDURE 1 Study with the Optilume® Ureteric Drug-Coated Balloon
Landmark procedures launch the ENDURE 1 clinical study evaluating Optilume's safety and feasibility as a new minimally invasive option for patients with benign ureteric strictures. PORTSMOUTH, N.H., ...
Optilume BPH is expected to have a significant global impact in urology, offering a novel alternative treatment option for enlarged prostate "We are proud at University Urology Associates to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results